Background: Interferons have been reported to significantly contribute to tumor suppression via both induction of p53 gene expression and inhibition of angiogenesis.
Objective: The assessment of treatment toxicity and antitumoral effectiveness of continuous IV administration of interferon-β based on an overall evaluation of laboratory, radiographic, and clinical parameters observed during the trial.
Methods: The authors treated patients with advanced malignant melanoma with continuous IV infusions of 1 × 106 IU interferon-β daily (0.6 × 106 IU interferon-β/m2 daily). Results: Continuous IV administration of interferon-β had no significant effect on overall patient outcome. Interferon side effects were not a reason for treatment discontinuation in any of the patients observed during this trial.
Conclusions: Continuous IV interferon-β had no significant effect on overall patient outcome in a group of patients with advanced malignant melanoma. To our knowledge, this is the first report on the continuous IV administration of interferon-β in patients with advanced malignant melanoma.